[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100389720":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":23,"locations":34,"responsibleParty":53,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":67,"sex":68,"minAge":10,"maxAge":10,"enrollmentInfo":69,"targetDuration":10,"studyType":72,"phases":10,"briefSummary":73,"conditions":74,"keywords":77,"overallStatus":37,"whyStopped":10,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of California, Los Angeles","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1",null,"Xiidra (Lifitegrast ophthalmic solution) 5% applied to both eye (OU) for 12 weeks",[13],"Drug: Xiidra (Lifitegrast ophthalmic solution) 5%",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Xiidra (Lifitegrast ophthalmic solution) 5%","FDA approved lifitegrast opthalmic solution eye drop",[9],[21,22],"Lifitegrast ophthalmic solution","SAR-1118",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Benjamin B Bert, MD","CONTACT","626-817-4701","BBert@mednet.ucla.edu",{"name":30,"role":26,"phone":31,"phoneExt":32,"email":33},"Mayra Raygoza","16268174747","19093","Mraygoza@mednet.ucla.edu",[35],{"facility":36,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Doheny Eye Center UCLA","RECRUITING","Fountain Valley","California","92708","United States","US",{"type":44,"coordinates":45},"Point",[46,47],-117.95367,33.70918,{"lat":47,"lon":46},[50],{"name":25,"role":26,"phone":51,"phoneExt":10,"email":52},"7149631444","JanettMendez@mednet.ucla.edu",{"type":54,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Benjamin B. Bert, MD","Health Sciences Assistant Professor",[58],{"name":59,"class":60},"Bausch & Lomb Incorporated","INDUSTRY","100389720","treatment-of-ocular-discomfort-in-glaucoma-patients-using-multiple-topical-medications-100389720",false,"NCT04354545","Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications","Inclusion Criteria:\n\n* Currently using one or more topical glaucoma antihypertensives\n* Self-described symptoms of ocular surface discomfort\n* Xiidra is being prescribed as part of the subject's standard care\n\nExclusion Criteria:\n\n* History of glaucoma filtration surgery, history of ocular surface surgery (pterygium, conjunctivoplasty, etc.),\n* current use of topical cyclosporine\n* current use of topical steroids\n* incisional ocular surgery within 6 months",true,"ALL",{"count":70,"type":71},75,"ESTIMATED","OBSERVATIONAL","To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.",[75,76],"Glaucoma","Ocular Surface Disease",[78,79,80],"glaucoma","xiidra™","ocular surface discomfort","2026-03-11",{"date":83,"type":84},"2026-03-13","ACTUAL",{"date":86,"type":84},"2021-04-01",{"date":88,"type":71},"2026-12-01",{"name":5,"class":6},1]